TP53 and colorectal cancer: Approaches to overcome the disadvantage of cisplatin in the treatment of unresponsive cancers include administration of cisplatin-derived compounds with activity in resistant cancer and application of drugs which interfere with p53-mediated signaling and will be described, with a special emphasis given to colorectal cancer.